Abstract Sickle Cell Disease (SCD) is a chronic hemolytic disorder associated with frequent
pain episodes, end organ damage and a shortened lifespan. Currently there exist no
disease specific targeted therapies for the treatment of acute vaso-occlusive crisis (VOC)
and management with analgesics and hydration is purely supportive. Improvement in
understanding of disease pathophysiology has resulted in a great interest in disease
modifying novel therapies and many are being evaluated in clinical trials. Here we report the …